Key result
Apixaban linked to ~23% lower monthly all-cause costs vs LMWH in cancer patients with VTE.
Why the study?
The study evaluated and compared healthcare costs associated with apixaban versus low molecular weight heparin in cancer patients with venous thromboembolism.
Does apixaban reduce healthcare costs compared to low molecular weight heparin in cancer patients with venous thromboembolism?
Cohort
Does apixaban reduce healthcare costs compared to low molecular weight heparin in cancer patients with venous thromboembolism?
In cancer patients with VTE, apixaban is associated with significantly lower all-cause and complication-related healthcare costs compared to LMWH.
Answers are grounded in this paper and cite their sources.
Apixaban was associated with lower costs than LMWH in cancer VTE; hypothesis-generating and should not yet change practice.
Objective This study evaluated and compared healthcare costs associated with apixaban versus low molecular weight heparin (LMWH) treatment among cancer patients who have venous thromboembolism (VTE).Methods A retrospective database analysis was conducted using IQVIA’s PharMetrics Plus healthcare claims database, from which patients with active cancer newly diagnosed with VTE and who initiated apixaban or LMWH on or within 30 days following the VTE diagnosis were identified. Data from 01 January 2016 through 31 December 2021 were analyzed, including a 12-month baseline and a variable (minimum one month) follow-up period. Stabilized inverse probability treatment weighting (IPTW) was applied to balance patient characteristics between treatment cohorts. All-cause costs were assessed along with recurrent VTE-, major bleeding (MB), and clinically relevant non-major (CRNM) bleeding-related costs. Two-part generalized linear models (GLM) were used to calculate cost ratios for apixaban vs. LMWH, and bootstrapping was implemented to estimate predicted costs. Costs were expressed as per patient per month (PPPM).Results Apixaban was associated with significantly lower predicted mean PPPM all-cause costs compared with the LMWH cohort ($16,408 vs. $21,203, p < 0.0001), with 23% lower PPPM costs versus LMWH (cost ratio: 0.77; 95% confidence interval [CI]: 0.74–0.81). Recurrent VTE-, MB-, and CRNM bleeding-related predicted costs were also lower with apixaban ($713 vs. $1274 [p < 0.0001], $518 vs. $1244 [p < 0.0001], and $733 vs. $980 [p = 0.014], respectively) compared to LMWH.Conclusion Among cancer patients with VTE, apixaban was associated with lower all-cause, recurrent-VTE-, MB-, and CRNM bleeding-related predicted costs compared with LMWH.
No takes yet. Share an insight, caveat, or question.
Hines et al. (2026) conducted a cohort in Venous thromboembolism (VTE) with active cancer. Apixaban vs. Low molecular weight heparin (LMWH) was evaluated on All-cause costs per patient per month (PPPM) (cost ratio 0.77, 95% CI 0.74-0.81, p=< 0.0001). Apixaban was associated with lower predicted mean per-patient-per-month all-cause costs compared with LMWH among cancer patients with VTE.
Synapse has enriched 10 related papers. Consider them for comparative context: